Skip to content
Open access

An integrated SOX4-driven transcriptional and metabolic program governs tumor-infiltrating regulatory T cells in ovarian cancer

Aug 2026 · Theranostics · Vol 16, pp. 8611 - 8632 · 0 citations · 48 references
Medicine

TL;DR

SOX4 is a central regulator of TI-Treg suppressive function and metabolic fitness, representing a promising therapeutic target for OC.

Abstract

Background Regulatory T cells (Tregs) suppress antitumor immunity in ovarian cancer (OC) and are promising targets for immunotherapy. However, the heterogeneity and regulatory mechanisms of tumor-infiltrating Tregs (TI-Tregs) remain poorly defined. Here, we aim to delineate TI-Treg programs to identify potential therapeutic targets. Methods CD4⁺CD25⁺CD127⁻ Tregs from OC, adjacent tissues, and peripheral blood were profiled by single-cell RNA sequencing and spatial transcriptomics, with regulatory networks inferred using SCENIC. Functional and mechanistic studies of SOX4 were performed using hypoxic/tumor-conditioned models, CRISPR–Cas9 perturbation, ectopic overexpression, Cut&Tag profiling, and oxidative phosphorylation (OXPHOS) inhibition. Results We identified nine transcriptionally distinct Treg subsets, revealing a highly activated and immunosuppressive state among TI-Tregs. These TI-Tregs exhibited strong co-expression of TNFRSF4, TNFRSF9, TNFRSF18, and CTLA4, and their increased intratumoral abundance was independently associated with poorer overall survival. SCENIC analysis identified SOX4 as the top regulon defining TI-Treg identity, with spatial transcriptomics revealing SOX4⁺ Tregs forming an immunoregulatory barrier at tumor margins. This phenotypic identity was robustly induced by the hypoxic microenvironment and TCR stimulation in a well-established murine OC model. Mechanistically, SOX4 transactivated MT1X to promote mitochondrial fitness and OXPHOS. Consistently, Cut&Tag profiling showed reduced chromatin accessibility at OXPHOS-related loci following SOX4 depletion. Furthermore, CRISPR–Cas9-mediated disruption of SOX4 reduced FOXP3 expression and other suppressive markers, whereas SOX4 overexpression enhanced FOXP3 expression in an OXPHOS-dependent manner. Notably, pharmacological inhibition of OXPHOS abolished this effect. Conclusions SOX4 is a central regulator of TI-Treg suppressive function and metabolic fitness, representing a promising therapeutic target for OC.

Read PDF

Similar papers

Open access Aug 2026

Single-cell profiling identifies STAT3/NF-κB regulatory hubs and cytokine crosstalk in the tumor microenvironment

Integrative single-cell RNA sequencing analysis of publicly available datasets from non-small cell lung cancer and breast cancer is performed to systematically map transcriptional heterogeneity and regulatory networks within the TME, providing a systems-level framework of TME organization.

M. O. Odubote, Chiemeka Elochi Emeribe · 0 citations
Review Open access Aug 2026

Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities

Targeting the mechanisms regulating Treg recruitment, stability, or suppressive function may represent a promising strategy to enhance the efficacy of immunotherapies including Bacillus Calmette–Guérin therapy.

Yusuke Fukiage, Nodoka Okubo, M. Taga et al. · 0 citations
Open access Sep 2026

CRISPR Screen and Single-Cell Multi-Omics Identify a Novel Immune Checkpoint on Tumor-Infiltrating Regulatory T Cells

Tumor infiltration regulatory T cells (Tregs) mediate immune escape by highly expressing multiple inhibitory receptors, which is one of the key factors in resistance to existing immune checkpoint inhibitors. However, systematic screening of Treg-specific immune checkpoints within tumors remains lacking. This study aims...

Gang Liu, Jia Wang, Li-Qiang An · 0 citations
Open access Aug 2026

Single-cell RNA sequencing reveals pro-tumorigenic intestinal mast cell programs in colorectal cancer

These findings identify a tumor-adapted MC state that orchestrates immune evasion and tissue remodeling during CRC progression, supporting the notion that MC are reprogrammed toward an immune-suppressive and pro-tumorigenic phenotype.

E. Putro, Alessia Carnevale, Caterina Marangio et al. · 0 citations
Sep 2026

Targeting PPP1R14B overcomes immunotherapy resistance in prostate cancer by restoring CD8+ T-cell infiltration via the Nrf2/CX3CL1 axis.

Prostate cancer (PCa) is typically immunologically 'cold', which limits the effectiveness of immunotherapy, and this study sought to identify key genes driving this immunosuppressive phenotype and assess their therapeutic potential. We analyzed transcriptomic data from 487 TCGA-PRAD patients and three Gene Expression O...

Jie Yang, Chuan Zhou, Wen-Bo Zhang et al. · 0 citations
Open access Sep 2026

CRISPRa-identified transcription factors reprogram glioblastoma into dendritic cell-like cells to elicit systemic antitumor immunity

Summary Although immunotherapy has transformed the treatment landscape for many types of cancer, its therapeutic efficacy in glioblastoma (GBM) is limited by insufficient antigen presentation and the immunogenic cell exclusion in the tumor microenvironment. Here, we develop a candidate-based CRISPR activation (CRISPRa)...

Xiao Liu, Mao-Rong Zhu, Cheng Zou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.